Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846052 | 0.82 | HTRA1 (0.35) | MEN1KMT2AHSD11B1CHRM2CHRM1 | |
| SCHEMBL5556528 | 0.73 | MAPT (0.47) | KMT2AHTT | |
| SCHEMBL13286306 | 0.70 | CHRM2 (0.39) | MEN1KMT2ANR1H2HSD11B1AR | |
| SCHEMBL19152862 | 0.70 | CHRM2 (0.39) | MEN1KMT2ANR1H2HSD11B1AR | |
| SCHEMBL20005947 | 0.70 | HTRA1 (0.50) | MEN1KMT2ANR1H2 | |
| SCHEMBL18089587 | 0.69 | MEN1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL18089591 | 0.69 | MEN1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL12481022 | 0.69 | MEN1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL20005725 | 0.68 | DPP4 (0.40) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL19995546 | 0.68 | DPP4 (0.40) | NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-106008569-B | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-04-03 | — | — | CN | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| US-10098902-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| CN-106008569-A | Boronates as arginase inhibitors, compositions and applications thereof | 马尔斯公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3034509-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2632927-B1 | BORONATES AS ARGINASE INHIBITORS | MARS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103249737-A | Borate as arginase inhibitor | MARS INC | 2013-08-14 | — | — | CN | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-10098902-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | MEN1 3256/4885KMT2A 1050/4885NR1H2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.